Dr. Stephen T. Hobson received a BS (cum laude) in Analytical/Inorganic Chemistry from Wheaton College (IL) in 1992. He received his Ph.D. in Organic and Materials Chemistry from the University of California, Irvine in 1997 in the group of Professor Kenneth J. Shea. His Ph.D. research was on the synthesis and characterization of organic bridged polysilsesquioxanes for use as high surface area materials, NLO applications, low dielectric constant materials, and high capacity selective metal adsorbents. In 1998 Dr. Hobson entered active duty (CPT, MSC) in the United States Army as a Principal Investigator at the United States Army Medical Research Institute of Chemical Defense (USARMICD) in Aberdeen Proving Ground, MD. At USAMRICD he gained extensive knowledge and experience in CWA physical and toxicological properties, protective schemes, and medical countermeasures. He also became familiarized with BWA by his review of SBIR proposal and his successful completion of the Medical Management of Chemical and Biological Casualties Course in 1998. His primary research involved research and development of an active topical skin protectant that prevent injury from percutaneous exposure of chemical warfare agents (CWAs) and neutralize the CWA. This project resulted in the award of a U.S. Army Research and Development Achievement Award in 2000. At USAMRICD he was appointed Director of the Chemical Synthesis Laboratory and performed research into the synthesis and SAR of novel compounds as medical countermeasures to blister (HD) and nerve agents (GD). Doctor Hobson eventually reached the rank of Major in the U. S. Army Reserve. In May 2003, Dr. Hobson joined Senomyx, Inc. as a Senior Scientist leading the synthesis and optimization of g-PCR active agonists, allosteric enhancers, and antagonists. In March 2005, Dr. Hobson joined Seacoast Science as the Senior Research Scientist with a focus on novel materials and biological applications of MEMS-chemicapacitive sensors. In 2006 he became Principal Scientist at Seacoast Science in charge of polymer/material development and development of sensors to novel applications and in 2009 he was promoted to Director of Chemistry. Since 2013 he has acted as a consultant/program manager for Rubicon Biotechnology LLC, a company based in Lake Forest, that is developing an antidote for phosgene inhalation. Dr. Hobson has (co)authored peer-reviewed journal articles (11), patents (14), and patent applications (2) in the fields of medicinal chemistry, chemical agent protection-decontamination, and high capacity hybrid organic-inorganic materials as metal sorbents. His current research projects include: the development of a badge-sized radiation sensor (NIEHS); the development of an ammonia and carbon dioxide sensor for space suits (NASA); and the advanced development of a sensor for the detection of cyanide in human blood (NIH CounterACT).